- IsoPlexis’ CodePlex solutions for high-plex automated immunoassays provides more comprehensive data in less time than other bulk population assay platforms using ultra-low sample volumes.
- Researchers at Johns Hopkins University used IsoPlexis’ CodePlex Secretome technology to investigate the role of cytokine signaling in promoting cell migration and cell density changes associated with cancer cell metastasis. IsoPlexis’ platform found a novel IL-6 and IL-8 mediated synergistic paracrine signaling pathway which may provide a new therapeutic target against metastatic cancer cells.
- Researchers at Yale used IsoPlexis’ CodePlex solution to analyze CSF and plasma samples from a COVID-19 patient who presented with neurological symptoms. IsoPlexis’ technology identified biomarkers of neuroinflammation as well as a unique MCP-1 signature in the patient’s CSF but not the plasma, while multiple COVID-19 tests detected the virus in the plasma but not the CSF. These findings led the researchers to conclude that neurological symptoms of COVID-19 may be driven by neuroinflammation rather than viral invasion of the brain.
IsoPlexis’ Platform Provides Highly Multiplexed Proteomics with CodePlex Using Very Low Sample Volumes
As a leader in single-cell functional proteomics, IsoPlexis provides deep functional insights across a range of disciplines, making an otherwise laborious process accessible and efficient with the IsoLight automated proteomics hub. In addition to its unique single-cell capabilities, IsoPlexis offers a faster and completely automated solution for highly multiplexed bulk assays, providing a superior alternative to other available bulk assay platforms. The CodePlex chips allow researchers to simply load their samples and walk away and runs on the automated IsoLight system just like the single-cell IsoCode chips. With only five minutes of prep time, researchers can run their experiment and obtain fully analyzed data same day, while other bulk technologies require numerous lengthy manual steps and can take days or longer to analyze the data, requiring specialized personnel.
CodePlex Solution Helps Researchers Identify Therapeutic Target for Treatment & Preventing Metastasis
In contrast to traditional technologies, IsoPlexis’ high-plex automated immunoassays provide researchers the ability to highly multiplex (e.g. 30+ cytokines) and fully automate proteomics for accelerated insights. The CodePlex family of solutions uses ultra-small sample volumes of 11 µL per sample, enabling critical applications across research disciplines from cancer immunology to infectious diseases, as evidenced by the use of CodePlex solutions in multiple recent high-impact publications. In a study led by Denis Wirtz at Johns Hopkins University, researchers investigated the role of cytokines in promoting or preventing metastatic cancer cell phenotypes. IsoPlexis’ CodePlex Secretome technology detected synergistic IL-6 and IL-8 mediated signaling pathways that promoted increased cell migration and cell density.1 Additionally, the study uncovered a novel IL-6 and IL-8 mediated synergistic paracrine signaling pathway which may provide a new therapeutic target against metastatic cancer cells. This finding highlights the critical use of functional cytokine assays in cancer immunology research, and points to a potential therapeutic target for the treatment and prevention of cancer cell metastasis.
IsoPlexis’ High-Plex Automated Immunoassays Reveal Underlying Mechanisms Driving Neurological COVID-19 Symptoms
IsoPlexis’ CodePlex Secretome solution has equally vital applications in the field of infectious disease research, specifically in COVID-19. The ability to detect specific cytokines with single-cell proteomics or cytokines within ultra-small sample volumes of both plasma and cerebrospinal fluid (CSF) is critical for understanding disease mechanisms, as well as for vaccine and therapeutic development.
Dr. Shelli Farhadian of Yale used IsoPlexis’ CodePlex Secretome technology to study the role cytokines and neuroinflammation play in COVID-19 patients who initially present with neurological symptoms. Researchers analyzed samples from the patient’s CSF and plasma and compared the results to three healthy controls. Elevated inflammatory cytokines were detected in both plasma and CSF; however, the most interesting discovery was a unique MCP-1 signature found only in the patient’s CSF, which did not test positive for COVID-19. This demonstrates that while the patient was infected with COVID-19, the neurological complications were not from viral invasion into the brain, but rather increased inflammation. IsoPlexis’ functional proteomics revealed unique cytokine signatures and uncovered mechanisms of central nervous system inflammation that may be associated with neurologic manifestations of disease.2
IsoPlexis’ CodePlex solution makes running highly multiplexed cytokine assays simpler and easier with a flexible, scalable, and automated platform. CodePlex produces population-level data 20x faster than other protein multiplexing systems, accelerating next-generation personalized curative medicines.
To learn more about how IsoPlexis’ CodePlex solution accelerates insights, watch this webinar with Dr. Denis Wirtz.
- Jayatilaka H, et al.Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration. Nature Communications 8: 15584, 2017.
- Farhadian S, et al. Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. BMC Neurology 20: 284, 2020.